553 related articles for article (PubMed ID: 25671669)
1. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
2. Conformational variation of an extreme drug resistant mutant of HIV protease.
Shen CH; Chang YC; Agniswamy J; Harrison RW; Weber IT
J Mol Graph Model; 2015 Nov; 62():87-96. PubMed ID: 26397743
[TBL] [Abstract][Full Text] [Related]
3. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Yu Y; Wang J; Shao Q; Shi J; Zhu W
Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
[TBL] [Abstract][Full Text] [Related]
4. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
5. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
6. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Chen J; Peng C; Wang J; Zhu W
Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
[TBL] [Abstract][Full Text] [Related]
7. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR; Wang Y
J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
[TBL] [Abstract][Full Text] [Related]
8. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
9. Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
Agniswamy J; Louis JM; Roche J; Harrison RW; Weber IT
PLoS One; 2016; 11(12):e0168616. PubMed ID: 27992544
[TBL] [Abstract][Full Text] [Related]
10. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
12. Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.
Purohit R; Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2011 Aug; 29(1):137-52. PubMed ID: 21696230
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.
Agniswamy J; Shen CH; Aniana A; Sayer JM; Louis JM; Weber IT
Biochemistry; 2012 Apr; 51(13):2819-28. PubMed ID: 22404139
[TBL] [Abstract][Full Text] [Related]
14. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
15. Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.
Hu G; Ma A; Dou X; Zhao L; Wang J
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240358
[TBL] [Abstract][Full Text] [Related]
16. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
[TBL] [Abstract][Full Text] [Related]
17. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
[TBL] [Abstract][Full Text] [Related]
18. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
19. Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Chen J; Liang Z; Wang W; Yi C; Zhang S; Zhang Q
Sci Rep; 2014 Nov; 4():6872. PubMed ID: 25362963
[TBL] [Abstract][Full Text] [Related]
20. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation.
Li D; Zhang Y; Zhao RN; Fan S; Han JG
J Mol Model; 2014 Feb; 20(2):2122. PubMed ID: 24526384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
